Heart failure & cardiomyopathies
Ten years real-world experience with sacubitril/valsartan in patients with heart failure with reduced ejection fraction
- systematic review
- real-world evidence
- PRISMA guidelines
- PubMed search through March 2024
+3 more
- real-world evidence
- PRISMA guidelines
- PubMed search through March 2024
Authors' conclusion
Real-world data mirror the efficacy and safety profiles seen in randomized controlled trials, establishing Sac/Val as a cornerstone of HFrEF therapy. However, significant barriers remain, including delayed initiation and suboptimal dose titration. Enhancing clinician and patient awareness is needed to bridge these implementation gaps and fully realize the drug’s potential to reduce the global healthcare burden of HF.
Study context
- Population
- Patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan in real-world practicemanuscripts from 30 different studies, primarily from Europe (44%) and the US (30%)
- Participants
- 45 patients
- Comparison
- Sac/Val vs traditional renin angiotensin system inhibitors
Pooled result
As reported in the abstract
Lower risk of cardiovascular mortality with Sac/Val
10%-16%
Lower risk of heart failure (HF) hospitalization with Sac/Val
10%-38%
Lower risk of all-cause mortality with Sac/Val
10%-25%
Further pooled results
Cardiac reverse remodeling and mitral regurgitation
- Sac/Val significantly associated with cardiac reverse remodeling and lower-grade mitral regurgitation
Patients achieving target doses in clinical practice
- Patients achieving target doses
- 15%-25%
Safety
- Hypotension (most common reported adverse event with Sac/Val)
- up to 17.6%
Hypotension (most common reported adverse event with Sac/Val)
- Hypotension was the most common reported adverse event with Sac/Val (up to 17.6%); severe hyperkalaemia and renal decline were similar when compared with traditional renin angiotensin system inhibitors
Original publication
Summarised from the published abstract; every number is checked against it